Assessing outcomes of enhanced chronic disease care through patient education and a value-based formulary study (ACCESS)-study protocol for a 2×2 factorial randomized trial

David J T Campbell, Marcello Tonelli, Brenda Hemmelgarn, Chad Mitchell, Ross Tsuyuki, Noah Ivers, Tavis Campbell, Raj Pannu, Eric Verkerke, Scott Klarenbach, Kathryn King-Shier, Peter Faris, Derek Exner, Vikas Chaubey, Braden Manns, Interdisciplinary Chronic Disease Collaboration, David J T Campbell, Marcello Tonelli, Brenda Hemmelgarn, Chad Mitchell, Ross Tsuyuki, Noah Ivers, Tavis Campbell, Raj Pannu, Eric Verkerke, Scott Klarenbach, Kathryn King-Shier, Peter Faris, Derek Exner, Vikas Chaubey, Braden Manns, Interdisciplinary Chronic Disease Collaboration

Abstract

Background: Chronic diseases result in significant morbidity and costs. Although medications and lifestyle changes are effective for improving outcomes in chronic diseases, many patients do not receive these treatments, in part because of financial barriers, patient and provider-level knowledge gaps, and low patient motivation. The Assessing outcomes of enhanced chronic disease care through patient education and a value-based formulary study (ACCESS) will determine the impact of two interventions: (1) a value-based formulary which eliminates copayment for high-value preventive medications; and (2) a comprehensive self-management support program aimed at promoting health behavior change and medication adherence, combined with relay of information on medication use to healthcare providers, on cardiovascular events and/or mortality in low-income seniors with elevated cardiovascular risk.

Methods: The ACCESS study will use a parallel, open label, factorial randomized trial design, with blinded endpoint evaluation in 4714 participants who are over age >65 (and therefore have drug insurance provided by Alberta Blue Cross with 30 % co-payment); are at a high risk for cardiovascular events based on a history of any one of the following: coronary heart disease, prior stroke, chronic kidney disease, heart failure, or any two of the following: current cigarette smoking, diabetes mellitus, hypertension, or hypercholesterolemia; and have a household income <Can$50,000. This 3-year study is powered to detect a minimal clinically important relative risk reduction of 12 % in the composite clinical outcome of all-cause mortality, nonfatal myocardial infarction, nonfatal stroke, need for coronary revascularization, and hospitalizations for chronic disease-related ambulatory care sensitive conditions, each of which will be assessed using healthcare administrative data. Secondary outcomes will include quality of life and healthcare costs.

Discussion: Given identified gaps in care in chronic disease, and the frequency of financial and knowledge-related barriers in low-income Albertans, this study will test the impact of providing free high-value preventive medications (i.e., value-based insurance) and a tailored self-management education and facilitated relay strategy on outcomes and costs. By measuring the impact on both health outcomes and costs, as well as the impact on reducing health inequities in this vulnerable population, our study will facilitate informed policy decisions.

Trial registration: Clinicaltrials.gov: NCT02579655 . Registered Oct 15, 2015.

Keywords: Chronic disease; Cost; Drug insurance; Education; Randomized clinical trial.

References

    1. World Health Organization. Cardiovascular diseases. . Accessed 5 Jul 2016.
    1. Statistics Canada . Mortality, summary list of causes. Ottawa: Statistics Canada; 2011.
    1. Leibowitz A, Manning WG, Newhouse JP. The demand for prescription drugs as a function of cost-sharing. Soc Sci Med. 1985;21:1063–9. doi: 10.1016/0277-9536(85)90161-3.
    1. Keeler EB, Brook RH, Goldberg GA, Kamberg CJ, Newhouse JP. How free care reduced hypertension in the health insurance experiment. JAMA. 1985;254:1926–31. doi: 10.1001/jama.1985.03360140084030.
    1. Tamblyn R, Laprise R, Hanley JA, Abrahamowicz M, Scott S, Mayo N, et al. Adverse events associated with prescription drug cost-sharing among poor and elderly persons. JAMA. 2001;285:421–9. doi: 10.1001/jama.285.4.421.
    1. Psaty BM, Lumley T, Furberg CD, Schellenbaum G, Pahor M, Alderman MH, et al. Health outcomes associated with various antihypertensive therapies used as first-line agents: a network meta-analysis. JAMA. 2003;289:2534–44. doi: 10.1001/jama.289.19.2534.
    1. Gaede P, Vedel P, Parving HH, Pedersen O. Intensified multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: the Steno type 2 randomised study. Lancet. 1999;353:617–22. doi: 10.1016/S0140-6736(98)07368-1.
    1. Nelson KM, McFarland L, Reiber G. Factors influencing disease self-management among veterans with diabetes and poor glycemic control. J Gen Intern Med. 2007;22:442–7. doi: 10.1007/s11606-006-0053-8.
    1. Barnieh L, Clement F, Harris A, Blom M, Donaldson C, Klarenbach S, et al. A systematic review of cost-sharing strategies used within publicly-funded drug plans in member countries of the organisation for economic co-operation and development. PLoS One. 2014;9:e90434. doi: 10.1371/journal.pone.0090434.
    1. Campbell D, King-Shier K, Hemmelgarn B, Sanmartin C, Ronksley P, Weaver R, et al. Assessing the association of financial barriers on care and outcomes for patients with chronic disease. Health Rep. 2014;25.
    1. Alberta Blue Cross. Plans for individuals and families. Accessed. 5 Jul 2016.
    1. Daw JR, Morgan SG. Stitching the gaps in the Canadian public drug coverage patchwork? A review of provincial pharmacare policy changes from 2000 to 2010. Health Policy. 2012;104:19–26. doi: 10.1016/j.healthpol.2011.08.015.
    1. Interdisciplinary chronic disease collaboration. Barriers to Care for People with Chronic Health Conditions Survey. Accessed. 5 Jul 2016.
    1. Bodenheimer T, Lorig K, Holman H, Grumbach K. Patient self-management of chronic disease in primary care. JAMA. 2002;288:2469–75. doi: 10.1001/jama.288.19.2469.
    1. Ansari Z, Laditka JN, Laditka SB. Access to health care and hospitalization for ambulatory care sensitive conditions. Med Care Res Rev. 2006;63:719–41. doi: 10.1177/1077558706293637.
    1. Canadian Institute for Health Information (CIHI). Technical note: ambulatory care sensitive conditions (ACSC). Accessed. 5 Jul 2016.
    1. Friedman B, Basu J. The rate and cost of hospital readmissions for preventable conditions. Med Care Res Rev. 2004;61:225–40. doi: 10.1177/1077558704263799.
    1. Booth G, Hux J. Relationship between avoidable hospitalizations for diabetes mellitus and income level. Arch Intern Med. 2003;163:101–6. doi: 10.1001/archinte.163.1.101.
    1. Campbell D, Ronksley P, Barnabe C, Tonelli M, Hemmelgarn B, Manns B. The association of enrolment in primary care networks on diabetes care and outcomes in low income and first nations Albertans. Open Med. 2012;6:E155–65.
    1. Tang KL, Bamieh L, Mann B, Clement F, Campbell DJT, Hemmelgarn BR, et al. A systematic review of value-based insurance design in chronic diseases. Am J Manag Care. 2014;20:E229–40.
    1. Choudhry NK, Avorn J, Glynn RJ, Antman EM, Schneeweiss S, Toscano M, et al. Full coverage for preventive medications after myocardial infarction. N Engl J Med. 2011;365:2088–97. doi: 10.1056/NEJMsa1107913.
    1. Tricco AC, Ivers NM, Grimshaw JM, Moher D, Turner L, Galipeau J, et al. Effectiveness of quality improvement strategies on the management of diabetes: a systematic review and meta-analysis. Lancet. 2012;379:2252–61. doi: 10.1016/S0140-6736(12)60480-2.
    1. Serrano V, Rodriguez-Gutierrez R, Hargraves I, Gionfriddo MR, Tamhane S, Montori VM. Shared decision-making in the care of individuals with diabetes. Diabet Med. 2016;33:742–51. doi: 10.1111/dme.13143.
    1. Statistics Canada . Table 051-0001 Population by year, by province and territory. Ottawa: Statistics Canada; 2015.
    1. Cannon CP, Steinberg BA, Murphy SA, Mega JL, Braunwald E. Meta-analysis of cardiovascular outcomes trials comparing intensive versus moderate statin therapy. J Am Coll Cardiol. 2006;48:438–45. doi: 10.1016/j.jacc.2006.04.070.
    1. van Vark LC, Bertrand M, Akkerhuis KM, Brugts JJ, Fox K, Mourad JJ, et al. Angiotensin-converting enzyme inhibitors reduce mortality in hypertension: a meta-analysis of randomized clinical trials of renin-angiotensin-aldosterone system inhibitors involving 158,998 patients. Eur Heart J. 2012;33:2088–97. doi: 10.1093/eurheartj/ehs075.
    1. O’Connor PJ. Patient archetypes, physician archetypes, and tailored diabetes care. J Am Board Fam Pract. 2002;15:334–7.
    1. Horne R, Chapman SC, Parham R, Freemantle N, Forbes A, Cooper V. Understanding patients’ adherence-related beliefs about medicines prescribed for long-term conditions: a meta-analytic review of the Necessity-Concerns Framework. PLoS One. 2013;8:e80633. doi: 10.1371/journal.pone.0080633.
    1. Pedersini R, Vietri J. Comparison of the 4-item and 8-item morisky medication adherence scale in patients with type 2 diabetes. Value Health. 2014;17:A196. doi: 10.1016/j.jval.2014.03.1146.
    1. Afshar AE, Weaver RG, Lin M, Allan M, Ronksley PE, Sanmartin C, et al. Capacity and willingness of patients with chronic noncommunicable diseases to use information technology to help manage their condition: a cross-sectional study. CMAJ Open. 2014;2:E51–9. doi: 10.9778/cmajo.20130070.
    1. Manns BJ, Tonelli M, Zhang J, Campbell DJ, Sargious P, Ayyalasomayajula B, et al. Enrolment in primary care networks: impact on outcomes and processes of care for patients with diabetes. CMAJ. 2012;184:E144–52. doi: 10.1503/cmaj.110755.
    1. Hemmelgarn BR, Clement F, Manns BJ, Klarenbach S, James MT, Ravani P, et al. Overview of the Alberta kidney disease network. BMC Nephrol. 2009;10:30. doi: 10.1186/1471-2369-10-30.
    1. Manns B, Tonelli M, Culleton B, Faris P, McLaughlin K, Chin R, et al. A cluster randomized trial of an enhanced eGFR prompt in chronic kidney disease. Clin J Am Soc Nephro. 2012;7:565–72. doi: 10.2215/CJN.12391211.
    1. Hemmelgarn B, Manns B, Lloyd A, James MT, Klarenbach S, Quinn R, et al. Relation between kidney function, proteinuria, and adverse outcomes. JAMA. 2010;303:423–9. doi: 10.1001/jama.2010.39.
    1. Hemmelgarn BR, James MT, Manns BJ, O’Hare AM, Muntner P, Ravani P, et al. Rates of treated and untreated kidney failure in older vs younger adults. JAMA. 2012;307:2507–15. doi: 10.1001/jama.2012.6455.
    1. Hemmelgarn BR, Zhang JG, Manns BJ, James MT, Quinn RR, Ravani P, et al. Nephrology visits and health care resource use before and after reporting estimated glomerular filtration rate. JAMA. 2010;303:1151–8. doi: 10.1001/jama.2010.303.
    1. Tonelli M, Muntner P, Lloyd A, Manns BJ, Klarenbach S, Pannu N, et al. Risk of coronary events in people with chronic kidney disease compared with those with diabetes: a population-level cohort study. Lancet. 2012;380:807–14. doi: 10.1016/S0140-6736(12)60572-8.
    1. Gao S, Manns BJ, Culleton BF, Tonelli M, Quan H, Crowshoe L, et al. Access to health care among status aboriginal people with chronic kidney disease. CMAJ. 2008;179:1007–12. doi: 10.1503/cmaj.080063.
    1. Hux JE, Ivis F, Flintoft V, Bica A. Diabetes in Ontario: determination of prevalence and incidence using a validated administrative data algorithm. Diabetes Care. 2002;25:512–6. doi: 10.2337/diacare.25.3.512.
    1. Quan H, Khan N, Hemmelgarn BR, Tu K, Chen G, Campbell N, et al. Validation of a case definition to define hypertension using administrative data. Hypertension. 2009;54:1423–8. doi: 10.1161/HYPERTENSIONAHA.109.139279.
    1. Canadian Institute for Health Information (CIHI). Technical Note: ambulatory care sensitive conditions. Accessed. 5 July 2016.
    1. Lee DS, Donovan L, Austin PC, Gong Y, Liu PP, Rouleau JL, et al. Comparison of coding of heart failure and comorbidities in administrative and clinical data for use in outcomes research. Med Care. 2005;43:182–8. doi: 10.1097/00005650-200502000-00012.
    1. Austin PC, Daly PA, Tu JV. A multicenter study of the coding accuracy of hospital discharge administrative data for patients admitted to cardiac care units in Ontario. Am Heart J. 2002;144:290–6. doi: 10.1067/mhj.2002.123839.
    1. Kokotailo RA, Hill MD. Coding of stroke and stroke risk factors using international classification of diseases, revisions 9 and 10. Stroke. 2005;36:1776–81. doi: 10.1161/01.STR.0000174293.17959.a1.
    1. Quan H, Parsons GA, Ghali WA. Validity of information on comorbidity derived rom ICD-9-CCM administrative data. Med Care. 2002;40:675–85. doi: 10.1097/00005650-200208000-00007.
    1. Robitaille C, Bancej C, Dai S, Tu K, Rasali D, Blais C, et al. Surveillance of ischemic heart disease should include physician billing claims: population-based evidence from administrative health data across seven Canadian provinces. BMC Cardiovasc Disord. 2013;13:88. doi: 10.1186/1471-2261-13-88.
    1. Quan H, Sundararajan V, Halfon P, Fong A, Burnand B, Luthi JC, et al. Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care. 2005;43:1130–9. doi: 10.1097/01.mlr.0000182534.19832.83.
    1. Choudhry NK, Shrank WH, Levin RL, Lee JL, Jan SA, Brookhart MA, et al. Measuring concurrent adherence to multiple related medications. Am J Manag Care. 2009;15:457–64.
    1. Pharmacy Quality Alliance. Adherence. Accessed. 5 July 2016.
    1. Karve S, Cleves MA, Helm M, Hudson TJ, West DS, Martin BC. Good and poor adherence: optimal cut-point for adherence measures using administrative claims data. Curr Med Res Opin. 2009;25:2303–10. doi: 10.1185/03007990903126833.
    1. Janssen MF, Lubetkin EI, Sekhobo JP, Pickard AS. The use of the EQ-5D preference-based health status measure in adults with Type 2 diabetes mellitus. Diabet Med. 2011;28:395–413. doi: 10.1111/j.1464-5491.2010.03136.x.
    1. Sach TH, Barton GR, Doherty M, Muir KR, Jenkinson C, Avery AJ. The relationship between body mass index and health-related quality of life: comparing the EQ-5D, EuroQol VAS and SF-6D. Int J Obes (Lond) 2007;31:189–96. doi: 10.1038/sj.ijo.0803365.
    1. Culleton BF, Walsh M, Klarenbach S, Mortis G, Scott-Douglas N, Quinn R, et al. Effect of frequent nocturnal hemodialysis vs conventional hemodialysis on left ventricular mass and quality of life: a randomized controlled trial. JAMA. 2007;298:1291–9. doi: 10.1001/jama.298.11.1291.
    1. Euroqoul. EQ-5D-5 L. Accessed. 5 July 2016.
    1. Bansback N, Tsuchiya A, Brazier J, Anis A. Canadian valuation of EQ-5D health states: preliminary value set and considerations for future valuation studies. PLoS One. 2012;7:e31115. doi: 10.1371/journal.pone.0031115.
    1. Fernandez S, Chaplin W, Schoenthaler AM, Ogedegbe G. Revision and validation of the medication adherence self-efficacy scale (MASES) in hypertensive African Americans. J Behav Med. 2008;31:453–62. doi: 10.1007/s10865-008-9170-7.
    1. Horne R, Weinman J, Hankins M. The beliefs about medicines questionnaire: the development and evaluation of a new method for assessing the cognitive representation of medication. Psychol Health. 1999;14:1–24. doi: 10.1080/08870449908407311.
    1. Vuong QH. Likelihood ratio tests for model selection and non-nested hypotheses. Econometrica. 1989;57:307–33. doi: 10.2307/1912557.
    1. McBrien KA, Manns BJ, Chui B, Klarenbach SW, Rabi D, Ravani P, et al. Health care costs in people with diabetes and their association with glycemic control and kidney function. Diabetes Care. 2013;36:1172–80. doi: 10.2337/dc12-0862.
    1. Klarenbach S, Tonelli M, Pauly R, Walsh M, Culleton B, So H, et al. Economic evaluation of frequent home nocturnal hemodialysis based on a randomized controlled trial. J Am Soc Nephrol. 2013.
    1. Rash JA, Cambell DJT, Tonelli M, Campbell T. A systematic review of interventions to improve adherence to statin medication: what do we know about what works? Prev Med. In press
    1. Pladevall M, Divine G, Wells KE, Resnicow K, Williams LK. A randomized controlled trial to provide adherence information and motivational interviewing to improve diabetes and lipid control. Diabetes Educ. 2015;41:136–46. doi: 10.1177/0145721714561031.

Source: PubMed

Sponsorit ja yhteistyökumppanit

Sairaudet

Huumeiden interventiot

3
Tilaa